A SYBR Green 1-based in vitro test of susceptibility of Ghanaian Plasmodium falciparum clinical isolates to a panel of anti-malarial drugs

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Quashie, Neils B ^a,b   Duah, Nancy O ^b   Abuaku, Benjamin ^b   Quaye, Lydia ^b   Ayanful Torgby, Ruth ^b   Akwoviah, George A ^b   Kweku, Margaret ^d   Johnson, Jacob D ^e   Lucchi, Naomi W ^f   Udhayakumar, Venkatachalam ^f   Duplessis, Christopher ^c   Kronmann, Karl C ^c   Koram, Kwadwo A ^b  

^a UNIVERSITY OF GHANA   (Ghana)

^b University of Ghana   (Ghana)

^c US Naval Medical Research Unit No 3 Egypt   (Egypt)

^d Hohoe Health Research Centre   (Ghana)

^e KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^f CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

in vitro; Inhibition; Isolates; Plasmodium falciparum; Susceptibility

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; ARTEMETHER; ARTEMISININ DERIVATIVE; ARTESUNATE; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; DIHYDROARTEMISININ; DOXYCYCLINE; FLUORESCENT DYE; MEFLOQUINE; PIPERAQUINE; QUININE; TAFENOQUINE;

ANTIMALARIAL DRUG SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; CROSS RESISTANCE; DRUG EFFICACY; GHANA; HEALTH CARE FACILITY; HEALTH CARE POLICY; HUMAN; IN VITRO STUDY; MALARIA; PLASMODIUM FALCIPARUM;

ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG RESISTANCE; GHANA; HUMANS; INFANT; INHIBITORY CONCENTRATION 50; MALARIA, FALCIPARUM; ORGANIC CHEMICALS; PLASMODIUM FALCIPARUM;

EID: 84890288815     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-450     Document Type: Article

References (57)

1. WHO, World Malaria Report, 2012 Geneva: World Health Organization 2013
2. Regional Strategies. RBM, 2013 http://www.rollbackmalaria.org/gmap/part3. pdf
3. MOH, Malaria report, 2008 Ghana: Ministry of Health 2009
4. Malaria in Ghana-overview. Ahmed K, Ghana Med J 1989 22 190 196
5. Malaria, action at last. Chinnock P, Afr Health Sci 1997 19 12 13
6. NMCP, Annual Report of the National Malaria Control Programme of Ghana, 2005 Ghana: Ministry of Health 2006
7. Comparative efficacy of antimalarial drugs including ACTs in the treatment of uncomplicated malaria among children under 5 years in Ghana. Koram KA, Abuaku B, Duah N, Quashie N, Acta Trop 2005 95 194 203 (Pubitemid 41207282)
8. Artemisinin resistance in Plasmodium falciparum malaria. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, Lwin KM, Ariey F, Hanpithakpong W, Lee SJ, Ringwald P, Silamut K, Imwong M, Chotivanich K, Lim P, Herdman T, An SS, Yeung S, Singhasivanon P, Day NP, Lindegardh N, Socheat D, White NJ, N Engl J Med 2009 361 455 467
9. Multi normal in vitro distribution model suitable for the distribution of Plasmodium falciparum chemo-susceptibility to doxycycline. Briolant S, Baragatti M, Parola P, Simon F, Tall A, Sokhna C, Hovette P, Mamfoumbi MM, Koeck JL, Delmont J, Spiegel A, Castello J, Gardair JP, Trape JF, Kombila M, Minodier P, Fusai T, Rogier C, Pradines B, Antimicrob Agents Chemother 2009 53 688 695
10. Ringwald P, Assessment and Monitoring of Antimalarial Drug Efficacy for the Treatment of Uncomplicated Falciparum Malaria Geneva, Switzerland: World Health Organization 2003
11. Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Bacon DJ, Latour C, Lucas C, Colina O, Ringwald P, Picot S, Antimicrob Agents Chemother 2007 51 1172 1178 (Pubitemid 46586790)
12. World antimalarial resistance network (WARN) II: in vitro antimalarial drug susceptibility. Bacon DJ, Jambou R, Fandeur T, Le BJ, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE, Malar J 2007 6 120
13. In vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, quinine, mefloquine and halofantrine in Abidjan (Cote d'Ivoire). Yavo W, Bla KB, Djaman AJ, Assi SB, Basco LK, Mazabraud A, Kone M, Afr Health Sci 2010 10 111 116
14. Assessment and continued validation of the malaria SYBR green I-based fluorescence assay for use in malaria drug screening. Johnson JD, Dennull RA, Gerena L, Lopez-Sanchez M, Roncal NE, Waters NC, Antimicrob Agents Chemother 2007 51 1926 1933 (Pubitemid 46903075)
15. The in-vitro susceptibilities of Ghanaian Plasmodium falciparum to antimalarial drugs. Quashie NB, Duah NO, Abuaku B, Koram KA, Ann Trop Med Parasitol 2007 101 391 398 (Pubitemid 47488127)
16. ICEstimator (version 1.2). http://www.antimalarialicestimator.net/ MethodIntro.htm
17. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from Africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Kaddouri H, Nakache S, Houze S, Mentre F, Le BJ, Antimicrob Agents Chemother 2006 50 3343 3349 (Pubitemid 44527508)
18. Online analysis of in vitro resistance to antimalarial drugs through nonlinear regression. Le NH, Vincent C, Mentre F, Le BJ, Comput Methods Programs Biomed 2011 104 10 18
19. Emergence of mefloquine-resistant malaria in Africa without drug pressure. Brasseur P, Kouamouo J, Moyou RS, Druilhe P, Lancet 1990 336 59 (Pubitemid 20207921)
20. [In vitro activity of various antimalarials (chloroquine, amodiaquine, quinine and mefloquine) against 32 isolates of Plasmodium falciparum in French Guiana](in French). Dedet JP, Germanetto P, Cordoliani G, Bonnevie O, Le BJ, Bull Soc Pathol Exot Filiales 1988 81 88 93
21. Reduced in vitro susceptibility to artemisinin derivatives associated with multi-resistance in a traveller returning from South-East Asia. Pradines B, Bertaux L, Pomares C, Delaunay P, Marty P, Malar J 2011 10 268
22. In vitro responses of Plasmodium falciparum isolates to five antimalaria drugs in French Guiana during 1994 and 1995. Reynes JM, Fargette J, Gaborit P, Yarde S, Mem Inst Oswaldo Cruz 1997 92 251 252
23. Association between the pfmdr1 gene and in vitro artemether and lumefantrine sensitivity in Thai isolates of Plasmodium falciparum. Mungthin M, Khositnithikul R, Sitthichot N, Suwandittakul N, Wattanaveeradej V, Ward SA, Na-Bangchang K, Am J Trop Med Hyg 2010 83 1005 1009
24. Gene encoding a deubiquitinating enzyme is mutated in artesunate- and chloroquine-resistant rodent malaria parasites. Hunt P, Afonso A, Creasey A, Culleton R, Sidhu AB, Logan J, Valderramos SG, McNae I, Cheesman S, Do RV, Carter R, Fidock DA, Cravo P, Mol Microbiol 2007 65 27 40 (Pubitemid 46934481)
25. In vitro response of Plasmodium falciparum to atovaquone and correlation with other antimalarials: comparison between African and Asian strains. Gay F, Bustos D, Traore B, Jardinel C, Southammavong M, Ciceron L, Danis MM, Am J Trop Med Hyg 1997 56 315 317 (Pubitemid 27181019)
26. Apparent absence of atovaquone/proguanil resistance in 477 Plasmodium falciparum isolates from untreated French travellers. Musset L, Pradines B, Parzy D, Durand R, Bigot P, Le Bras J, J Antimicrob Chemother 2006 57 110 115 (Pubitemid 43057066)
27. In vitro responses of Plasmodium falciparum parasites to chloroquine, amodiaquine and quinine in two ecological zones in Ghana. Afari EA, Akanmori BD, Nakano T, Ofori-Adjei D, Cent Afr J Med 1993 39 136 140 (Pubitemid 24247785)
28. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Smilkstein M, Sriwilaijaroen N, Kelly JX, Wilairat P, Riscoe M, Antimicrob Agents Chemother 2004 48 1803 1806 (Pubitemid 38544392)
29. In vitro susceptibility of Plasmodium falciparum isolates to chloroquine and other antimalarial drugs in Ghana. Quashie NB, Ofori-Adjei D, Duah NO, Koram K, Ghana Med J 2004 38 131 135
30. Re-emergence of chloroquine-sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. Kublin JG, Cortese JF, Njunju EM, Mukadam RA, Wirima JJ, Kazembe PN, Djimde AA, Kouriba B, Taylor TE, Plowe CV, J Infect Dis 2003 187 1870 1875 (Pubitemid 36724485)
31. Return of chloroquine antimalarial efficacy in Malawi. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, Taylor TE, Plowe CV, N Engl J Med 2006 355 1959 1966 (Pubitemid 44708015)
32. Chloroquine resistance before and after its withdrawal in Kenya. Mwai L, Ochong E, Abdirahman A, Kiara SM, Ward S, Kokwaro G, Sasi P, Marsh K, Borrmann S, Mackinnon M, Nzila A, Malar J 2009 8 106
33. Longitudinal study assessing the return of chloroquine susceptibility of Plasmodium falciparum in isolates from travellers returning from West and Central Africa, 2000-2011. Gharbi M, Flegg JA, Hubert V, Kendjo E, Metcalf JE, Bertaux L, Guerin PJ, Le BJ, Aboubaca A, Agnamey P, Angoulvant A, Barbut P, Basset D, Belkadi G, Bellanger AP, Bemba D, Benoit-Vica F, Berry A, Bigel ML, Bonhomme J, Botterel F, Bouchaud O, Bougnoux ME, Bouree P, Bourgeois N, Branger C, Bret L, Buret B, Casalino E, Chevrier S, et al. Malar J 2013 12 35
34. Mutations in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance genes, and treatment outcomes in Ghanaian children with uncomplicated malaria. Duah NO, Wilson MD, Ghansah A, Abuaku B, Edoh D, Quashie NB, Koram KA, J Trop Pediatr 2007 53 27 31 (Pubitemid 46201476)
35. A molecular marker for chloroquine-resistant falciparum malaria. Djimde A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourte Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV, N Engl JMed 2001 344 257 263 (Pubitemid 32108530)
36. Mutations in the P. falciparum digestive vacuole transmembrane protein PFCRT and evidence for their role in chloroquine resistance. Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, Ursos LM, Sidhu AB, Naudé B, Deitsch KW, Su XZ, Wootton JC, Roepe PD, Wellems TE, Mol Cel 2000 6 861 871
37. Several alleles of the multidrug-resistance gene are closely linked to chloroquine resistance in Plasmodium falciparum. Foote SJ, Kyle DE, Martin RK, Oduola AM, Forsyth K, Kemp DJ, Cowman AF, Nature 1990 345 255 258
38. Increased pfmdr1 gene copy number and the decline in pfcrt and pfmdr1 resistance allelles in Ghanaian Plasmodium falciparum isolates after the change of antimalarial drug treatment policy. Duah NO, Matrevi SA, de Souza DK, Binnah DD, Tamakloe MM, Opoku VS, Onwona CO, Narh CA, Quashie NB, Abuaku B, Duplessis C, Kronmann KC, Koram KA, Malar J 2013 12 377
39. The roles of the pfcrt 76 T and pfmdr1 86Y mutations, immunity and the initial level of parasitaemia, in predicting the outcome of chloroquine treatment in two areas with different transmission intensities. Khalil IF, Alifrangis M, Tarimo DS, Staalso T, Satti GM, Theander TG, Ronn AM, Bygbjerg IC, Ann Trop Med Parasitol 2005 99 441 448 (Pubitemid 40992388)
40. MOH, Anti-Malaria Drug Policy for Ghana Accra, Ghana: Ministry of Health 2009
41. Administrative practices of health professionals and use of artesunate-amodiaquine by community members for treating uncomplicated malaria in southern Ghana: implications for artemisinin-based combination therapy deployment. Kwansa-Bentum B, Ayi I, Suzuki T, Otchere J, Kumagai T, Anyan WK, Asahi H, Akao N, Wilson MD, Boakye DA, Ohta N, Trop Med Int Health 2011 16 1215 1224
42. United Nation General Assembly, Implementation of General Assembly Resolution 66/289 on Consolidating Gains and Accelerating Efforts to Control and Eliminate Malaria in Developing Countries, Particularly in Africa, by 2015 2012 United Nation document A/RES/66/289
43. WHO, WHO Informal Consultation with Manufacturers of Artemisinin-Based Pharmaceutical Products in use for the Treatment of Malaria Geneva: World Health Organization 2007
44. WHO briefing on Malaria Treatment Guidelines and artemisinin monotherapies. WHO, 2006 http://www.who.int/malaria/publications/atoz/meeting- briefing19april.pdf
45. Phenotype and genotype analysis of in vitro-selected artemisinin- resistance progeny of plasmodium falciparum. Tucker M, Mutka T, Sparks K, Patel J, Kyle DE, Antimicrob Agent Chemother 2012 56 302 314
46. Novel pheno typic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia in vitro and ex-vivo drug-response studies. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B, Anderson JM, Duong S, Chuor CM, Taylor WR, Suon S, Mercereau-Puijalon O, Fairhurst RM, Menard D, Lancet Infect Dis 2013 13 1043 1049
47. MOH, Guidelines for Case Management of Malaria in Ghana Accra: Ministry of Health 2009
48. Survey of the quality of selected antimalarial medicines circulating in six countries of sub-Saharan Africa. WHO, 2011 http://www.who.int/medicines/ publications/WHO-QAMSA-report.pdf
49. Reduced in-vitro susceptibility to mefloquine in West African isolates of Plasmodium falciparum. Oduola AM, Milhous WK, Salako LA, Walker O, Desjardins RE, Lancet 1987 2 1304 1305 (Pubitemid 17156637)
50. Reduced sensitivity of Plasmodium falciparum to mefloquine in West Africa. Simon F, Le BJ, Gaudebout C, Girard PM, Lancet 1988 1 467 468 (Pubitemid 18067691)
51. Tafenoquine: a promising new antimalarial agent. Crockett M, Kain KC, Expert Opin Investig Drugs 2007 16 705 715 (Pubitemid 46723273)
52. In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti. Pradines B, Mamfoumbi MM, Tall A, Sokhna C, Koeck JL, Fusai T, Mosnier J, Czarnecki E, Spiegel A, Trape JF, Kombila M, Rogier C, Antimicrob Agents Chemother 2006 50 3225 3226 (Pubitemid 44396447)
53. Oxygen- and time-dependent effects of antibiotics and selected mitochondrial inhibitors on Plasmodium falciparum in culture. Divo AA, Geary TG, Jensen JB, Antimicrob Agents Chemother 1985 27 21 27 (Pubitemid 15198148)
54. Evaluation of a range of antimicrobial agents against the parasitic protozoa, Plasmodium falciparum, Babesia rodhaini and Theileria parva in vitro. McColm AA, McHardy N, Ann Trop Med Parasitol 1984 78 345 354 (Pubitemid 14060022)
55. Effects of minocycline against chloroquine-resistant falciparum malaria. Willerson D Jr, Rieckmann KH, Carson PE, Frischer H, Am J Trop Med Hyg 1972 21 857 862
56. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Dahl EL, Rosenthal PJ, Antimicrob Agents Chemother 2007 51 3485 3490 (Pubitemid 47519333)
57. WHO, Global Plan for Artemisinin Resistance Containment (GPARC) Geneva: World Health Organization 2011